Anti-VEGF treatment for choroidal neovascularization complicating pattern dystrophy-like deposit associated with pseudoxanthoma elasticum.

Abstract

PURPOSE:

To evaluate the efficacy of intravitreal anti-VEGF injections in choroidal neovascularization (CNV) related to pattern dystrophy-like deposit in pseudoxanthoma elasticum (PXE).

METHODS:

One-year prospective, interventional study. Nine eyes were recruited in the ophthalmology departments of San Raffaele University and University of Barcelona. Each patient underwent best corrected visual acuity (BCVA) measurement on ETDRS chart, slit-lamp biomicroscopy, fluorescein angiography (FA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT). The protocol included a first anti-VEGF injection, followed by monthly evaluations with re-treatments based on new funduscopic hemorrhages, fluid on OCT or leakage on FA and/or ICGA. Primary outcome measures were the mean BCVA changes. Secondary outcomes included central macular thickness (CMT) variations and the number of injections needed.

RESULTS:

At month 12, mean BCVA significantly improved from 20/45 to 20/35 Snellen equivalent, with 3 eyes gaining at least 3 ETDRS lines. Mean CMT decreased from 297 ± 22 to 262 ± 13 μm, after 5.5 ± 4.0 injections. No leakage was observed at the end of follow-up.

CONCLUSIONS:

Intravitreal anti-VEGF injections represent an effective treatment for CNV related to pattern dystrophy-like deposit in PXE, with an improvement of BCVA and CMT. Mean injection number is in line with other studies performed in CNV secondary to angioid streaks.

• Authors: Maurizio Battaglia Parodi, Francesco Romano, Alessandro Marchese, Alessandro Arrigo, Victor Llorenç, Maria Vittoria Cicinelli, Francesco Bandello, Alfredo Adán
• Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (Graefes Arch Clin Exp Ophthalmol) Vol. 257 Issue 2 Pg. 273-278 (Feb 2019) ISSN: 1435-702X [Electronic] Germany
• PMID: 30470876 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Angiogenesis Inhibitors
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Aged
• Angiogenesis Inhibitors (administration & dosage)
• Bevacizumab (administration & dosage)
• Choroidal Neovascularization (diagnosis, drug therapy, etiology)
• Female
• Fluorescein Angiography (methods)
• Follow-Up Studies
• Fundus Oculi
• Humans
• Intravitreal Injections
• Male
• Middle Aged
• Prospective Studies
• Pseudoxanthoma Elasticum (complications, diagnosis, drug therapy)
• Retinal Dystrophies (complications, diagnosis, drug therapy)
• Time Factors
• Tomography, Optical Coherence (methods)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity